SG11201406185WA - Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases - Google Patents
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinasesInfo
- Publication number
- SG11201406185WA SG11201406185WA SG11201406185WA SG11201406185WA SG11201406185WA SG 11201406185W A SG11201406185W A SG 11201406185WA SG 11201406185W A SG11201406185W A SG 11201406185WA SG 11201406185W A SG11201406185W A SG 11201406185WA SG 11201406185W A SG11201406185W A SG 11201406185WA
- Authority
- SG
- Singapore
- Prior art keywords
- disubstitued
- pyridine
- triazolo
- imidazo
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1262CH2012 | 2012-03-30 | ||
PCT/IB2013/051577 WO2013144737A2 (fr) | 2012-03-30 | 2013-02-27 | Nouveaux composés 3,5-disubstitués-3h-imidazo[4,5-b]pyridines et 3,5-disubstitués-3h-[1,2,3]triazolo[4,5-b]pyridines en tant que modulateurs des protéines kinases c-met |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201406185WA true SG11201406185WA (en) | 2014-11-27 |
Family
ID=48093046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406185WA SG11201406185WA (en) | 2012-03-30 | 2013-02-27 | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
Country Status (21)
Country | Link |
---|---|
US (3) | US9815831B2 (fr) |
EP (1) | EP2831073B1 (fr) |
JP (1) | JP6192708B2 (fr) |
KR (2) | KR20140144726A (fr) |
CN (2) | CN107082779A (fr) |
AP (1) | AP3908A (fr) |
AU (1) | AU2013239398B2 (fr) |
BR (1) | BR112014024251A8 (fr) |
CA (1) | CA2865719C (fr) |
CL (1) | CL2014002604A1 (fr) |
CO (1) | CO7111276A2 (fr) |
EA (1) | EA026412B1 (fr) |
ES (1) | ES2856848T3 (fr) |
HK (1) | HK1204612A1 (fr) |
IL (1) | IL234513B (fr) |
MX (1) | MX359888B (fr) |
MY (1) | MY169268A (fr) |
NZ (1) | NZ629499A (fr) |
PH (1) | PH12014502166B1 (fr) |
SG (1) | SG11201406185WA (fr) |
WO (1) | WO2013144737A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ703111A (en) * | 2010-05-17 | 2016-07-29 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
US9815831B2 (en) * | 2012-03-30 | 2017-11-14 | Rhizen Pharmaceuticals Sa | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases |
GB201321741D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
EP3325471A1 (fr) * | 2015-07-20 | 2018-05-30 | Genzyme Corporation | Inhibiteurs du récepteur de facteur-1 de stimulation de colonies (csf-1r) |
CN107573340B (zh) * | 2017-10-23 | 2020-11-24 | 江西科技师范大学 | 2-氨甲酰基-4-芳杂吡啶类化合物的制备及应用 |
GB201803892D0 (en) * | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
BR112022022409A2 (pt) | 2020-05-06 | 2023-02-07 | Ajax Therapeutics Inc | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 |
EP4267573A1 (fr) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Inhibiteurs deutérés du récepteur du facteur 1 de stimulation des colonies (csp-1r) |
TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
AU2022264784A1 (en) * | 2021-04-29 | 2023-11-16 | Amgen Inc. | Heterocyclic compounds and methods of use |
CN114031562A (zh) * | 2021-10-31 | 2022-02-11 | 南京碳硅人工智能生物医药技术研究院有限公司 | 一种具有抗肿瘤的吡啶衍生物的工艺优化 |
AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (fr) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Procede de fixation d'une proteine sur un substrat |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (fr) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Traduction non-disponible |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
AU610083B2 (en) | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO1993021259A1 (fr) | 1992-04-14 | 1993-10-28 | Cornell Research Foundation Inc. | Macromolecules dendritiques et leur procede de production |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
MX9708026A (es) | 1995-04-20 | 1997-11-29 | Pfizer | Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos. |
DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
ATE217315T1 (de) | 1996-07-18 | 2002-05-15 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
SK21499A3 (en) | 1996-08-23 | 2000-05-16 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
JP3338064B2 (ja) | 1997-01-06 | 2002-10-28 | ファイザー・インク | 環状スルホン誘導体 |
IL131042A0 (en) | 1997-02-03 | 2001-01-28 | Pfizer Prod Inc | Arylsulfonylamino hydroxamic acid derivatives |
JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
IL131123A0 (en) | 1997-02-11 | 2001-01-28 | Pfizer | Arylsulfonyl hydroxamic acid derivatives |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
DE60006649T2 (de) | 1999-02-22 | 2004-09-30 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | C-21 modifizierte epothilone |
EP1644528A2 (fr) | 2003-06-19 | 2006-04-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, | Variants des genes du recepteur du gout humain |
ATE389651T1 (de) | 2003-08-15 | 2008-04-15 | Vertex Pharma | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
EP1697352B1 (fr) | 2003-09-24 | 2012-06-27 | Vertex Pharmceuticals Incorporated | Compositions d'imidazole substitue par 4-azole utilisees comme inhibiteurs de c-met recepteur tyrosine kinase |
ES2925655T3 (es) | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
CA2545659C (fr) * | 2003-11-19 | 2013-06-04 | Array Biopharma Inc. | Inhibiteurs bicycliques de mek |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
JP5368701B2 (ja) | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
BRPI0514687A (pt) | 2004-08-26 | 2008-06-17 | Pfizer | compostos amino heteroarila como inibidores de proteìna tirosina cinase |
DK1786785T3 (da) | 2004-08-26 | 2010-05-31 | Pfizer | Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere |
ES2355923T3 (es) | 2004-08-26 | 2011-04-01 | Pfizer, Inc. | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa. |
MX337817B (es) | 2004-11-04 | 2011-11-04 | Vertex Pharma | Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas. |
JP2008537748A (ja) | 2005-04-06 | 2008-09-25 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
US7470693B2 (en) | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7728017B2 (en) | 2005-11-30 | 2010-06-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
DE602007004092D1 (de) | 2006-03-22 | 2010-02-11 | Vertex Pharma | C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen |
NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
TW200813021A (en) | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
NZ575548A (en) | 2006-09-18 | 2011-09-30 | Vertex Pharma | Heterocyclic inhibitors of c-Met and uses thereof |
WO2008051493A2 (fr) * | 2006-10-19 | 2008-05-02 | Signal Pharmaceuticals, Llc | Composés hétéroaryle, compositions contenant ces composés et procédés de traitement faisant appel à ces composés |
AU2007309237B2 (en) | 2006-10-23 | 2012-03-22 | Sgx Pharmaceuticals, Inc. | Triazolo-pyridazine protein kinase modulators |
CA2668210C (fr) | 2006-10-31 | 2013-03-12 | Schering Corporation | Derives d'anilinopiperazine et leurs methodes d'utilisation |
WO2008060866A1 (fr) | 2006-11-14 | 2008-05-22 | Smithkline Beecham Corporation | Nouveaux composés |
WO2008078085A1 (fr) | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Procédé |
US8551995B2 (en) | 2007-01-19 | 2013-10-08 | Xcovery Holding Company, Llc | Kinase inhibitor compounds |
CA2679602A1 (fr) | 2007-02-23 | 2008-08-28 | Eisai R&D Management Co., Ltd. | Derive de pyridine ou de pyrimidine ayant un excellent effet d'inhibition de la croissance cellulaire et un excellent effet antitumoral sur une souche de cellules ayant une amplification du gene hgfr |
FR2915198B1 (fr) * | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
US8304425B2 (en) | 2007-06-22 | 2012-11-06 | Arqule, Inc. | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer |
CA2703978A1 (fr) | 2007-10-29 | 2009-05-07 | Schering Corporation | Derives de la thiazole en tant qu'inhibiteurs de la proteine kinase |
CN101910167A (zh) | 2007-10-29 | 2010-12-08 | 先灵公司 | 噻唑甲酰胺衍生物及其治疗癌症 |
CA2703980A1 (fr) | 2007-10-29 | 2009-05-07 | Schering Corporation | Derives de diamidothiazole en tant qu'inhibiteurs de proteine kinase |
JP2011502160A (ja) | 2007-10-29 | 2011-01-20 | シェーリング コーポレイション | プロテインキナーゼ阻害剤としての複素環式尿素およびチオ尿素誘導体ならびにそれらの使用方法 |
PL2276346T3 (pl) * | 2008-04-30 | 2017-07-31 | National Health Research Institutes | Skondensowane bicykliczne związki pirymidynowe jako inhibitory kinazy aurora |
EP2719699B1 (fr) * | 2009-12-31 | 2015-07-08 | Hutchison Medipharma Limited | Certaines triazolopyrazines, leurs compositions et leurs procédés d'utilisation |
CN102127096A (zh) | 2009-12-31 | 2011-07-20 | 和记黄埔医药(上海)有限公司 | 三氮唑并吡啶和三氮唑并吡嗪化合物及其组合物和应用 |
NZ703111A (en) * | 2010-05-17 | 2016-07-29 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
US9815831B2 (en) * | 2012-03-30 | 2017-11-14 | Rhizen Pharmaceuticals Sa | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases |
US9887269B2 (en) * | 2015-11-30 | 2018-02-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-gate device and method of fabrication thereof |
-
2013
- 2013-02-27 US US14/389,336 patent/US9815831B2/en active Active
- 2013-02-27 KR KR1020147030532A patent/KR20140144726A/ko active Application Filing
- 2013-02-27 AP AP2014007966A patent/AP3908A/en active
- 2013-02-27 AU AU2013239398A patent/AU2013239398B2/en not_active Ceased
- 2013-02-27 ES ES13716061T patent/ES2856848T3/es active Active
- 2013-02-27 CN CN201710062943.0A patent/CN107082779A/zh active Pending
- 2013-02-27 EA EA201491520A patent/EA026412B1/ru unknown
- 2013-02-27 WO PCT/IB2013/051577 patent/WO2013144737A2/fr active Application Filing
- 2013-02-27 BR BR112014024251A patent/BR112014024251A8/pt not_active IP Right Cessation
- 2013-02-27 MX MX2014011750A patent/MX359888B/es active IP Right Grant
- 2013-02-27 MY MYPI2014002712A patent/MY169268A/en unknown
- 2013-02-27 SG SG11201406185WA patent/SG11201406185WA/en unknown
- 2013-02-27 CA CA2865719A patent/CA2865719C/fr active Active
- 2013-02-27 KR KR1020207002779A patent/KR102164317B1/ko active IP Right Grant
- 2013-02-27 EP EP13716061.0A patent/EP2831073B1/fr active Active
- 2013-02-27 JP JP2015502481A patent/JP6192708B2/ja not_active Expired - Fee Related
- 2013-02-27 CN CN201380022471.6A patent/CN104321322A/zh active Pending
- 2013-02-27 NZ NZ629499A patent/NZ629499A/en not_active IP Right Cessation
-
2014
- 2014-09-07 IL IL234513A patent/IL234513B/en active IP Right Grant
- 2014-09-26 PH PH12014502166A patent/PH12014502166B1/en unknown
- 2014-09-29 CL CL2014002604A patent/CL2014002604A1/es unknown
- 2014-10-28 CO CO14238774A patent/CO7111276A2/es unknown
-
2015
- 2015-05-29 HK HK15105126.9A patent/HK1204612A1/xx unknown
-
2017
- 2017-09-14 US US15/705,005 patent/US11066402B2/en active Active
-
2021
- 2021-05-30 US US17/303,494 patent/US20210371416A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP3908A (en) | Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases | |
ZA201906379B (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
IL235819A0 (en) | Preparation of pyrrolo[b–3,2]pyridines | |
ZA201406148B (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
ZA201406149B (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
IL246177B (en) | History of dihydro- and tetrahydropyrido[4,3-b]pyrazine as gpr6 modulators | |
IL238493B (en) | Amino-substituted imidazo[a–2,1]pyridinecarboxamides and their use | |
AP2013007147A0 (en) | Use of substituted 2,3-dihydroimidazo[1,2-C]quinyzolines | |
PT2935274T (pt) | Derivados de 3-oxo-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3- a]pirimidina para o tratamento de doenças respiratórias | |
HK1217658A1 (zh) | 基於吡唑並 嘧啶的化合物、包含其的組合物和其使用方法 | |
EP2854528B8 (fr) | Traitement de tumeurs solides au moyen de la coenzyme q10 | |
ZA201406323B (en) | Triazolo[4,5-d]pyrimidine derivatives | |
HK1204610A1 (zh) | 作為治療增殖性病症的 調節劑的咪唑並 吡啶衍生物 | |
ZA201500865B (en) | Process for the preparation of sitagliptin and intermediate compounds | |
HK1205504A1 (en) | Substituted pyrazolo[1,5-a]pyridines, their preparation and use as medicaments [1,5-a] | |
PT2870164T (pt) | Derivados de imidazo[2,1-b]tiazol, as suas preparações e utilização como medicamentos | |
HK1197244A1 (zh) | 用於 -苯基- 三唑並 吡啶衍生物的製備的方法 | |
IL259166A (en) | Novel 4h–chromen–4–one compounds as protein kinase modulators |